tradingkey.logo

Biofrontera Inc

BFRI
0.766USD
+0.006+0.72%
收盘 12/19, 16:00美东报价延迟15分钟
8.92M总市值
亏损市盈率 TTM

Biofrontera Inc

0.766
+0.006+0.72%

关于 Biofrontera Inc 公司

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

Biofrontera Inc简介

公司代码BFRI
公司名称Biofrontera Inc
上市日期Oct 14, 2021
CEOLuebbert (Hermann)
员工数量92
证券类型Ordinary Share
年结日Oct 14
公司地址120 Presidential Way,
城市WOBURN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01801
电话17812451325
网址https://www.biofrontera-us.com/
公司代码BFRI
上市日期Oct 14, 2021
CEOLuebbert (Hermann)

Biofrontera Inc公司高管

名称
名称/职务
职务
持股
持股变动
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
152.71K
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
87.50K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Mr. George Jones
Mr. George Jones
Chief Commercial Officer
Chief Commercial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
152.71K
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
87.50K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--

收入明细

FY2024
FY2023
FY2022
FY2021
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
37.32M
0.00%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.79%
AIGH Capital Management, LLC.
7.86%
Hewlett Fund, L.P.
4.05%
Biofrontera AG
3.43%
Lytton (Laurence W)
2.63%
其他
72.23%
持股股东
持股股东
占比
Rosalind Advisors, Inc.
9.79%
AIGH Capital Management, LLC.
7.86%
Hewlett Fund, L.P.
4.05%
Biofrontera AG
3.43%
Lytton (Laurence W)
2.63%
其他
72.23%
股东类型
持股股东
占比
Hedge Fund
12.69%
Private Equity
8.36%
Corporation
7.49%
Individual Investor
4.70%
Investment Advisor/Hedge Fund
2.49%
Investment Advisor
1.67%
Venture Capital
0.15%
Research Firm
0.05%
其他
62.39%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
34
2.85M
28.39%
--
2025Q3
35
2.85M
24.13%
+509.58K
2025Q2
38
2.48M
28.99%
+6.08K
2025Q1
43
1.91M
35.97%
-1.28M
2024Q4
42
2.24M
20.22%
+365.98K
2024Q3
37
1.95M
35.26%
+44.70K
2024Q2
40
1.95M
40.02%
-47.81K
2024Q1
39
1.85M
15.80%
+1.04M
2023Q4
36
279.45K
16.52%
+54.33K
2023Q3
39
75.19K
10.29%
-23.48K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Rosalind Advisors, Inc.
644.39K
6.04%
--
--
Aug 13, 2025
AIGH Capital Management, LLC.
914.21K
8.57%
--
--
Aug 13, 2025
Hewlett Fund, L.P.
550.22K
5.16%
--
--
Aug 13, 2025
Biofrontera AG
400.00K
3.75%
--
--
Sep 16, 2025
Lytton (Laurence W)
306.70K
2.87%
-228.98K
-42.75%
Mar 31, 2025
Armistice Capital LLC
291.15K
2.73%
+141.15K
+94.10%
Sep 30, 2024
Worth Venture Partners, LLC
249.36K
2.34%
-125.08K
-33.41%
Jun 30, 2025
Luebbert (Hermann)
152.71K
1.43%
+137.50K
+903.95%
Sep 10, 2025
The Vanguard Group, Inc.
14.92K
0.14%
--
--
Aug 31, 2025
Leffler (Eugene Frederick)
87.50K
0.82%
+87.50K
--
Sep 10, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
公告日期
类型
比率
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1

常见问题

Biofrontera Inc的前五大股东是谁?

Biofrontera Inc 的前五大股东如下:
Rosalind Advisors, Inc.持有股份:644.39K,占总股份比例:6.04%。
AIGH Capital Management, LLC.持有股份:914.21K,占总股份比例:8.57%。
Hewlett Fund, L.P.持有股份:550.22K,占总股份比例:5.16%。
Biofrontera AG持有股份:400.00K,占总股份比例:3.75%。
Lytton (Laurence W)持有股份:306.70K,占总股份比例:2.87%。

Biofrontera Inc的前三大股东类型是什么?

Biofrontera Inc 的前三大股东类型分别是:
Rosalind Advisors, Inc.
AIGH Capital Management, LLC.
Hewlett Fund, L.P.

有多少机构持有Biofrontera Inc(BFRI)的股份?

截至2025Q4,共有34家机构持有Biofrontera Inc的股份,合计持有的股份价值约为2.85M,占公司总股份的28.39%。与2025Q3相比,机构持股有所增加,增幅为4.26%。

哪个业务部门对Biofrontera Inc的收入贡献最大?

在FY2024,--业务部门对Biofrontera Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI